Available Therapeutic Options for Corneal Neovascularization: A Review
International Journal of Molecular Sciences · 17.05.2024 · 25 (10) · 5479
DOI: 10.3390/ijms25105479 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.05.2024. Verfasst von Łukasz Drzyzga und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Prof. K. Gibiński University Clinical Center, Medical University of Silesia, 40-055 Katowice, Poland. Hauptthemen laut MEDLINE: Corneal Neovascularization. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Corneal neovascularization can impair vision and result in a poor quality of life. The pathogenesis involves a complex interplay of angiogenic factors, notably vascular endothelial growth factor (VEGF). This review provides a comprehensive overview of potential therapies for corneal neovascularization, covering tissue inhibitors of metalloproteinases (TIMPs), transforming growth factor beta (TGF-β) inhibitors, interleukin-1L receptor antagonist (IL-1 Ra), nitric oxide synthase (NOS) isoforms, galectin-3 inhibitors, retinal pigment epithelium-derived factor (PEDF), platelet-derived growth factor (PDGF) receptor inhibitors, and surgical treatments. Conventional treatments include anti-VEGF therapy and laser interventions, while emerging therapies such as immunosuppressive drugs (cyclosporine and rapamycin) have been explored. Losartan and decorin are potential antifibrotic agents that mitigate TGF-β-induced fibrosis. Ocular nanosystems are innovative drug-delivery platforms that facilitate the targeted release of therapeutic agents. Gene therapies, such as small interfering RNA and antisense oligonucleotides, are promising approaches for selectively inhibiting angiogenesis-related gene expression. Aganirsen is efficacious in reducing the corneal neovascularization area without significant adverse effects. These multifaceted approaches underscore the corneal neovascularization management complexity and highlight ideas for enhancing therapeutic outcomes. Furthermore, the importance of combination therapies and the need for further research to develop specific inhibitors while considering their therapeutic efficacy and potential adverse effects are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Prof. K. Gibiński University Clinical Center, Medical University of Silesia, 40-055 Katowice, Poland.
- Clinical Ophthalmology Center Okolux, 40-754 Katowice, Poland.
- Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-514 Katowice, Poland.
ORCID-Profile: Dorota Śpiewak
Zitieren
APA
Drzyzga, Ł., Śpiewak, D., Dorecka, M., & Wyględowska-Promieńska, D. (2024). Available Therapeutic Options for Corneal Neovascularization: A Review. International Journal of Molecular Sciences, 25(10), 5479. https://doi.org/10.3390/ijms25105479
Vancouver
Drzyzga Ł, Śpiewak D, Dorecka M, Wyględowska-Promieńska D. Available Therapeutic Options for Corneal Neovascularization: A Review. International Journal of Molecular Sciences. 2024;25(10):5479. doi:10.3390/ijms25105479
BibTeX
@article{Drzyzga2024,
author = {Drzyzga, Łukasz and Śpiewak, Dorota and Dorecka, Mariola and Wyględowska-Promieńska, Dorota},
title = {Available Therapeutic Options for Corneal Neovascularization: A Review},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {10},
pages = {5479},
doi = {10.3390/ijms25105479}
}
EUVIMED